FindTrial
Sign In

Clinical Study on The SLEDAI-reducing and Glucocorticoid-withdrawing Effect of Compound Qinghao Oral Liquid on Mild to Moderate Systemic lupus erythematosus

Clinical Study on Compound Qinghao Oral Liquid for Mild to Moderate Systemic lupus erythematosus

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12002402
Enrollment
Unknown
Registered
2012-08-02
Start date
2012-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic lupus erythematosus

Interventions

two groups:Integrative TCM with Western medicine vs Placebo

Sponsors

Zhejinag University of f Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Complying with four or more items in the SLE western medicine diagnosis standard; the patients accord with liver-kidney Yin deficiency toxic heat and blood stasis; the SLE patients in mild- moderate period (5<=SLEDAI<=14); patients in the age between 18 and 60 years; patients who voluntary to enjoy the test and agree to sign informed consent certificates; patients did not use other related drugs within one week before experimental treatment.

Exclusion criteria

Exclusion criteria: The illness in severe active period; current dosage of prednisone >1mg/kg.d; merge use other immunosuppressive agents beyond glucocorticoid; merge of the fatal damage to target organs; pregnant and lactating women and mental patients

Design outcomes

Primary

MeasureTime frame
SLEDAI;dosage of glucocorticoid;—

Countries

China

Contacts

Public ContactFan Yong-sheng
fyszjtcm@163.com+86 0571 86613587

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026